Ikonisys SA (ALIKO) - Total Liabilities
Based on the latest financial reports, Ikonisys SA (ALIKO) has total liabilities worth €7.50 Million EUR (≈ $8.77 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ikonisys SA - Total Liabilities Trend (2019–2024)
This chart illustrates how Ikonisys SA's total liabilities have evolved over time, based on quarterly financial data. See Ikonisys SA current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Ikonisys SA Competitors by Total Liabilities
The table below lists competitors of Ikonisys SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
USA | $1.43 Million |
|
STAK Inc. Ordinary Shares
NASDAQ:STAK
|
USA | $13.85 Million |
|
Schlatter Industries AG
SW:STRN
|
Switzerland | CHF43.72 Million |
|
Nucletron Electronic Aktiengesellschaft
F:NUC
|
Germany | €2.08 Million |
|
Naas Technology Inc ADR
NASDAQ:NAAS
|
USA | $1.26 Billion |
|
Mobix Labs Inc
NASDAQ:MOBX
|
USA | $28.06 Million |
|
Eastparc Hotel Tbk PT
JK:EAST
|
Indonesia | Rp24.07 Billion |
|
Adore Beauty Group Ltd
AU:ABY
|
Australia | AU$69.04 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Ikonisys SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Ikonisys SA worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ikonisys SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ikonisys SA (2019–2024)
The table below shows the annual total liabilities of Ikonisys SA from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €13.14 Million ≈ $15.37 Million |
+156.73% |
| 2023-12-31 | €5.12 Million ≈ $5.99 Million |
+26.61% |
| 2022-12-31 | €4.04 Million ≈ $4.73 Million |
+61.43% |
| 2021-12-31 | €2.50 Million ≈ $2.93 Million |
+5.01% |
| 2020-12-31 | €2.39 Million ≈ $2.79 Million |
+16.79% |
| 2019-12-31 | €2.04 Million ≈ $2.39 Million |
-- |
About Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the flu… Read more